Single Use Bioreactors Market Updates

Single Use Bioreactors Market size was valued at USD 3.3 Billion in 2023 and is poised to grow from USD 3.87 Billion in 2024 to USD 14.13 Billion by 2032, growing at a CAGR of 17.19% during the forecast period (2025-2032).

The market is rapidly developing, and in the upcoming years, it is anticipated that market competition will rise. The increasing use of disposable bioreactors has led to an increase in new market entrants, which has in turn heightened competition. To maintain their market presence, the major market players are engaging in a number of strategic initiatives. One of the key strategies used by the major market players is the introduction of new products. Other key strategies include mergers and acquisitions and capacity expansion. 'Danaher (USA) ', 'Sartorius AG (Germany) ', 'Thermo Fisher Scientific (USA) ', 'Merck KGaA (Germany) ', 'Pall Corporation (USA) ', 'Eppendorf SE (Germany) ', 'ABEC (USA) ', 'Celltainer (Netherlands) ', 'Distek, Inc. (USA) ', 'OmniBRx Biotechnologies (India) ', 'PBS Biotech, Inc. (USA) ', 'GE Healthcare (USA) ', 'Cellexus Ltd. (UK) ', 'Pierre Guerin (France) ', 'CerCell ApS (Denmark) ', 'Bioengineering AG (Switzerland) ', 'Meissner Filtration Products (USA) ', 'Kuhner Shaker (Switzerland) ', 'Thermo Fisher Scientific (USA) '

Due to the growing geriatric population's increased susceptibility to a wide range of diseases, there is a rising demand for biopharmaceuticals on a global scale. Global corporations are concentrating on biopharmaceutical R&D and manufacturing for product development and increased production in response to this demand. 

Growing adoption in the bioprocessing sector: The high rate of adoption of SUBs in the bioprocessing sector is likely to augment the market share in the coming years. Owing to the benefits such as flexibility, scalability, and lower time costs offered through SUBs is likely to be witnessed.

North America maintained a huge dominance and is expected to continue a leading position owing to the presence of significant operating players and the region's well-established biopharmaceutical industry. Additionally, the region's increased manufacturing capacity has added to the market expansion. For instance, Thermo Fisher Scientific announced in September 2021 that it intended to build a new manufacturing facility specifically for single-use bioprocessing products. The addition of the Nashville location increased its network of SUT manufacturing facilities on a global scale. The changing environment for manufacturing and bioprocessing is a key driver of market expansion in the United States.